Azeria hit the ground running with £4 million Series A capital and a mandate to develop breakthrough treatments for hormone resistant breast cancer and prostate cancer patients.
The Cancer Research UK spin-out launched with backing from the £70 million CRT Pioneer Fund, managed by Sixth Element Capital LLP (6EC) in Hertfordshire. Azeria is a spin out created by Sixth Element Capital and Cancer Research UK’s commercial partnerships team.
It emerged from stealth branded as “the world’s first pioneer factor drug discovery company developing breakthrough treatments for hormone resistant breast and prostate cancer patients, where there are significant areas of unmet clinical need.”
The investment will be used to build on the discoveries made by founder Dr Jason Carroll, a globally renowned expert in pioneer factors in cancer at his lab at the Cancer Research UK Cambridge Institute at the University of Cambridge.
Using its proprietary drug screening platform, Azeria is developing a pipeline of small molecules designed to selectively inhibit pioneer factors.